Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Government of the United States of America | 23 |
| 2 | Battelle Memorial Institute Inc | 17 |
| 3 | Roche Holding AG | 16 |
| 4 | International Flavors and Fragrances Inc | 14 |
| 5 | Merck and Co Inc | 12 |
| 6 | Weizmann Institute of Science | 10 |
| 7 | Berkshire Hathaway Inc | 8 |
| 8 | Chinese Academy of Sciences | 7 |
| 9 | Cellectar Biosciences Inc | 6 |
| 10 | Takeda Pharmaceutical Co Ltd | 6 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C07K | Peptides | 154 |
| 2 | A61K | Medicinal preparations | 146 |
| 3 | A61P | Therapeutic activity (drug indications) | 121 |
| 4 | G01N | Investigating / analysing materials | 90 |
| 5 | C12N | Microorganisms, enzymes | 74 |
| 6 | C07D | Heterocyclic compounds | 52 |
| 7 | C12Q | Measuring/testing involving enzymes | 41 |
| 8 | C12P | Fermentation, enzyme processes | 31 |
| 9 | C07C | Acyclic and carbocyclic compounds | 22 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 21 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| ALPHA-AMYLASE COMBINATORIAL VARIANTS | 2014 | International Flavors and Fragrances Inc | 222 |
| Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines | 1991 | Eni SpA | 358 |
| SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | 2017 | 56 | |
| Cell delivery compositions | 2004 | Massachusetts Institute of Technology | 104 |
| HINGE DOMAIN ENGINEERING | 2009 | AstraZeneca PLC | 61 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | F. Ann Walker | University of Arizona | 3 |
| 2 | Masaru Miyagi | Case Western Reserve University | 2 |
| 3 | Rehab F. Abdelhamid | Ibaraki University | 2 |
| 4 | Rimma I. Samoilova | Institute of Chemical Kinetics and Combustion | 2 |
| 5 | Graham S. Jackson | University College London | 2 |
| 6 | John Collinge | University College London | 2 |
| 7 | Jonathan P. Waltho | University of Sheffield | 2 |
| 8 | Takamitsu Kohzuma | Ibaraki University | 2 |
| 9 | M A Wells | University of Sheffield | 2 |
| 10 | Sergei A. Dikanov | University of Illinois Urbana-Champaign | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Molecular Features of the Copper Binding Sites in the Octarepeat Domain of the Prion Protein | 2002 | 420 | Trace Elements in Health |
| Histidine phosphorylation in biological systems | 2007 | 91 | Enzyme Structure and Function |
| Mechanism of copper(II)-induced misfolding of Parkinson's disease protein | 2011 | 86 | Parkinson's Disease Mechanisms and Treatments |
| Direct Evidence That All Three Histidine Residues Coordinate to Cu(II) in Amyloid-β1−16 | 2008 | 85 | Protein Structure and Dynamics |
| Multiple forms of copper (II) co-ordination occur throughout the disordered N-terminal region of the prion protein at pH 7.4 | 2006 | 83 | Trace Elements in Health |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and weight of this compound?
Which organizations hold the most patents involving this compound?
What research topics are most commonly associated with this compound in the academic literature?
How has patent activity for this compound changed in recent years?
Which patent classification areas dominate the intellectual property landscape for this compound?